Literature DB >> 15232715

Prevention and therapy of osteoporosis: the roles of plain vitamin D and alfacalcidol.

Johann D Ringe1, Erich Schacht.   

Abstract

Severe vitamin D deficiency was identified only in the first decades of the last century as the most common aetiology of rickets in children and osteomalacia in adults. It was later shown that vitamin D is not, as had been supposed, the biologically active principle for healing bone disease but must be hydroxylated in the liver and then finally in the kidney to become 1alpha,25-dihydroxy-cholecalciferol, a biologically highly active renal hormone. This study reviews the various principles, mechanisms, and approaches to the treatment of different forms of osteoporosis using vitamin D, alfacalcidol, and calcitriol therapy regimens.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15232715     DOI: 10.1007/s00296-004-0454-0

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  64 in total

1.  Amelioration of osteopenia and hypovitaminosis D by 1alpha-hydroxyvitamin D3 in elderly patients with Parkinson's disease.

Authors:  Y Sato; S Manabe; H Kuno; K Oizumi
Journal:  J Neurol Neurosurg Psychiatry       Date:  1999-01       Impact factor: 10.154

Review 2.  Rationale for active vitamin D analog therapy in senile osteoporosis.

Authors:  K Akesson; K H Lau; D J Baylink
Journal:  Calcif Tissue Int       Date:  1997-01       Impact factor: 4.333

3.  Treatment of postmenopausal osteoporosis with high doses of synthetic calcitriol. A randomized controlled study.

Authors:  J C Gallagher; D Goldgar
Journal:  Ann Intern Med       Date:  1990-11-01       Impact factor: 25.391

4.  Combination treatment with estrogen and calcitriol in the prevention of age-related bone loss.

Authors:  J C Gallagher; S E Fowler; J R Detter; S S Sherman
Journal:  J Clin Endocrinol Metab       Date:  2001-08       Impact factor: 5.958

Review 5.  Use of oral corticosteroids and risk of fractures.

Authors:  T P Van Staa; H G Leufkens; L Abenhaim; B Zhang; C Cooper
Journal:  J Bone Miner Res       Date:  2000-06       Impact factor: 6.741

Review 6.  Recent advances in pediatric metabolic bone disease: the consequences of altered phosphate homeostasis in renal insufficiency and hypophosphatemic vitamin D-resistant rickets.

Authors:  J M Pettifor
Journal:  Bone Miner       Date:  1990-06

7.  Treatment of glucocorticoid-induced osteoporosis with alfacalcidol/calcium versus vitamin D/calcium.

Authors:  J D Ringe; A Cöster; T Meng; E Schacht; R Umbach
Journal:  Calcif Tissue Int       Date:  1999-10       Impact factor: 4.333

8.  Prevention of corticosteroid-induced osteoporosis by alfacalcidol.

Authors:  P Lakatos; Z Nagy; L Kiss; C Horvath; I Takacs; J Foldes; G Speer; A Bossanyi
Journal:  Z Rheumatol       Date:  2000       Impact factor: 1.372

9.  1, 25-dihydroxycholecalciferol in the pathogenesis of the hypercalcaemia of sarcoidosis.

Authors:  S E Papapoulos; T L Clemens; L J Fraher; I G Lewin; L M Sandler; J L O'Riordan
Journal:  Lancet       Date:  1979-03-24       Impact factor: 79.321

10.  Effect of alfacalcidol on natural course of renal bone disease in mild to moderate renal failure.

Authors:  N A Hamdy; J A Kanis; M N Beneton; C B Brown; J R Juttmann; J G Jordans; S Josse; A Meyrier; R L Lins; I T Fairey
Journal:  BMJ       Date:  1995-02-11
View more
  8 in total

1.  Questions on the superiority of alfacalcidol over plain vitamin D in the treatment of glucocorticoid-induced osteoporosis.

Authors:  Johann D Ringe
Journal:  Rheumatol Int       Date:  2004-10-13       Impact factor: 2.631

2.  Superiority of alfacalcidol compared to vitamin D plus calcium in lumbar bone mineral density in postmenopausal osteoporosis.

Authors:  R Nuti; G Bianchi; M L Brandi; R Caudarella; E D'Erasmo; C Fiore; G C Isaia; G Luisetto; M Muratore; P Oriente; S Ortolani
Journal:  Rheumatol Int       Date:  2005-11-10       Impact factor: 2.631

3.  Superiority of a combined treatment of Alendronate and Alfacalcidol compared to the combination of Alendronate and plain vitamin D or Alfacalcidol alone in established postmenopausal or male osteoporosis (AAC-Trial).

Authors:  J D Ringe; P Farahmand; E Schacht; A Rozehnal
Journal:  Rheumatol Int       Date:  2007-03       Impact factor: 2.631

4.  In elderly men and women treated for osteoporosis a low creatinine clearance of <65 ml/min is a risk factor for falls and fractures.

Authors:  Laurent Dukas; Erich Schacht; Hannes B Stähelin
Journal:  Osteoporos Int       Date:  2005-06-03       Impact factor: 4.507

5.  Alfacalcidol in men with osteoporosis: a prospective, observational, 2-year trial on 214 patients.

Authors:  J D Ringe; P Farahmand; E Schacht
Journal:  Rheumatol Int       Date:  2012-04-08       Impact factor: 2.631

Review 6.  Improving the outcome of established therapies for osteoporosis by adding the active D-hormone analog alfacalcidol.

Authors:  J D Ringe; E Schacht
Journal:  Rheumatol Int       Date:  2007-08-01       Impact factor: 2.631

7.  Synergistic effects of green tea polyphenols and alphacalcidol on chronic inflammation-induced bone loss in female rats.

Authors:  C-L Shen; J K Yeh; J J Cao; O L Tatum; R Y Dagda; J-S Wang
Journal:  Osteoporos Int       Date:  2010-01-13       Impact factor: 4.507

8.  Vitamin D-insufficiency: An estimate of the situation in Germany.

Authors:  Johann Diederich Ringe; Christoph Kipshoven
Journal:  Dermatoendocrinol       Date:  2012-01-01
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.